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Generic	formulations	of	small	molecules	are	usually	as	effective	as	originators,	have	
similar	harms,	and	are	cheaper	to	prescribe.	The	same	should	be	true	of	biosimilars,	
which	are	generic	equivalents	of	originator	biological	medicines	(biologics).1	
	 Two	years	ago2	we	cited	an	article	in	the	Financial	Times,3 whose author claimed that 
the UK had been slow to adopt biosimilars. Here we provide evidence that that is so, based 
on the limited publicly available information on NHS prescribing of biosimilars. 
	 Biosimilars	are	biologics	that	are	highly	similar	to	other	already	approved	biologics	
and	are	themselves	approved	according	to	the	same	standards	of	pharmaceutical	
quality,	safety,	and	efficacy.4	They	are	not	necessarily	identical.	Consider,	for	example,	
monoclonal	antibodies.	Although	a	biosimilar	is	likely	to	preserve	the	primary	amino	
acid	sequence	of	the	originator,	differences	in	glycosylation,	deamination,	oxidation,	or	
three‐dimensional	structure	can	occur.	These	can	affect	interactions	with	target	
molecules,	which	could	lead	to	differences	in	benefits,	harms,	or	both,	between	
biosimilars	and	the	corresponding	originators.	This	may	be	the	case,	for	example,	with	
epoetins.5,6	
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	 Clinicians	face	two	problems:	choosing	between	an	originator	or	a	biosimilar	when	
starting	therapy	and	whether	to	switch	from	one	to	the	other	during	established	
therapy.	
	 There	are	principles	to	ensure	that	biosimilars	are	similar	enough,7	and	US	and	
European	regulators	demand	that	biosimilars	should	be	“highly	similar	to	the	reference	
medicinal	product	in	physicochemical	and	biological	terms”.8	This	includes,	for	example,	
pharmacokinetic	and	pharmacodynamic	similarity,	and	being	used	in	the	same	dosages	
as	the	originator	product.	Furthermore,	“any	observed	differences	have	to	be	duly	
justified	with	regard	to	their	potential	impact	on	safety	and	efficacy.”	The	principles	are	
included	in	guidance	from	the	US	Food	and	Drug	Administration,9	and	NICE	has	
provisions	for	recommending	biosimilars	when	appropriate.10	
	 There	is	some	reassuring	evidence	of	equivalence.	For	example,	two	infliximab	
biosimilars,	Remsima	and	Inflectra11,12,13	are	identical	to	the	originator,	Remicade,	in	
pharmaceutical	form,	strength,	composition,	and	route	of	administration.	The	biological	
actions	of	Remsima	are	essentially	identical	to	those	of	Remicade,	apart	from	minor	
pharmacodynamic	differences	that	appear	to	be	clinically	insignificant.14	The	
pharmacokinetics	are	almost	identical,	and	clinical	markers	of	disease	activity	respond	
equally	well	to	originator	and	biosimilar	products	in	rheumatoid	arthritis	and	
ankylosing	spondylitis.	
	 The	WHO	plans	to	prequalify	biosimilars	for	cancer	therapy,	giving	them	a	global	
stamp	of	approval.15	Comparability	of	quality,	safety,	and	efficacy	will	make	them	
eligible	for	procurement	by	UN	agencies.	This	should	increase	assurance	of	equivalence.	
	 However,	showing	that	two	products	are	of	equal	efficacy	does	not	prove	that	
switching	them	maintains	the	balance	of	benefits	and	harms	in	individual	patients.	For	
example,	in	an	18‐month	study	in	inflammatory	bowel	disease,	switching	from	
originator	infliximab	to	a	biosimilar	did	not	affect	efficacy,	but	13/143	patients	dropped	
out	because	of	adverse	events.16	
	 A	systematic	review	of	58	studies,	including	12	clinical	trials,	mostly	involving	
infliximab	or	epoetins,	suggested	that	the	expected	cost	savings	of	switching	
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outweighed	the	risks	of	anticipated	harms.17	A	later	review	of	57	studies,	covering	a	
wider	range	of	compounds	(infliximab	and	epoetins,	but	also	adalimumab,	etanercept,	
filgrastim,	follicle	stimulating	hormone,	genotropin,	insulin	glargine,	and	rituximab),	
reported	that	safety	and	efficacy	were	mostly	unchanged	after	switching.18	However,	
the	data	were	limited,	and	the	authors	commented	that	well	powered	and	appropriately	
analysed	clinical	trials	and	pharmacovigilance	studies,	with	long‐term	follow‐up	and	
multiple	switches,	were	needed.	
	 We	sought	evidence	about	UK	prescribing	of	biosimilars	in	two	publicly	accessible	
sources:	OpenPrescribing.net,	a	freely	available	website	containing	detailed	current	
data	on	all	prescribing	in	individual	English	general	practices19;	and	the	NHS	Medicines	
Optimisation	Dashboard,	which	contains	a	limited	number	of	prespecified	measures	at	
the	individual	NHS	Trust	level.20	Insulin	glargine	is	commonly	prescribed	in	primary	
care,	and	detailed	data	are	available	through	OpenPrescribing.net:	the	originator,	
Lantus,	still	accounts	for	90%	of	GP	prescriptions	(Figure	1);	the	biosimilar	Abasaglar	
accounts	for	around	60%	of	the	increased	number	of	prescriptions	since	it	was	licensed	
in	September	2015.	This	suggests	that	40%	of	new	patients	are	still	receiving	the	
originator,	whose	NHS	indicative	price	is	7%	higher,	and	that	switching	is	rare.	No	other	
biosimilars	are	commonly	prescribed	in	primary	care,	and	hospital	prescribing	data	are	
limited:	from	the	large	number	of	biosimilars	now	available	(Table	1),	the	Medicines	
Optimisation	Dashboard	gives	information	on	only	three	(Table	2).	Uptake	has	been	
incomplete.	This	may	have	substantial	cost	implications,	as	prices	are	high	and	
originators	typically	cost	about	10%	more	than	biosimilars.21	
	 Reasons	for	the	poor	uptake	of	biosimilars	may	include	lack	of	familiarity,	
therapeutic	inertia,	concern	about	patient	confusion	over	different	brand	names	and	
different	looking	formulations,	perceived	lack	of	efficacy,	the	nocebo	effect,22	and	
apparently	modest	percentage	price	differences.	
	 When	a	biosimilar	has	been	licensed,	there	should	be	no	concerns	about	starting	
treatment	with	it	rather	than	the	originator.	Switching	to	a	cheaper	product	in	a	patient	
who	is	already	taking	an	originator	can	also	be	recommended	when	there	is	high	quality	
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evidence	of	equivalence	of	the	benefits	and	harms,	provided	progress	is	then	carefully	
monitored.	
	
Table	1.	Examples	of	biosimilars	currently	approved	in	the	EU	and/or	USA	
	
Generic	
name*	
Originator	brand	
name	(company)	
Examples	of	biosimilar	brand	names	
(company)	
Adalimumaba	 Humira	(AbbVie)	 Imraldi	(Samsung	Bioepis/Merck)	
Darbepoetinb	 Aranesp	(Amgen)	 Retacrit	(epoetin	zeta;	Hospira)	
Silapo	(epoetin	zeta;	Stada	Arzneimittel)	
Epoetin	alfab	 Epogen/Eprex/Procrit	
(epoetin	alfa;	Amgen/	
Johnson	&	Johnson)	
Abseamed	(Medice	Arzneimittel	Pütter)	
Binocrit	(Sandoz)	
Etanerceptc	 Enbrel	
(Amgen/Pfizer)	
Brenzys/Benepali	(Samsung	Bioepis/Merck)	
Erelzi	(Sandoz)	
Filgrastimb	 Neupogen	(Amgen)	 Biograstim	(CT	Arzneimittel)	
Filgrastim	Hexal	(Hexal)		
Grastofil	(Apotex)	
Infliximaba	 Remicade	(Johnson	&	
Johnson/Merck)		
Flixabi/Renflexis	(Samsung	Bioepis/Merck)	
Remsima/Inflectra/Flammegis	
(Celltrion/Hospira)	
Insulin	
glargined	
Lantus	(Sanofi)	 Abasaglar/Basaglar	(Eli	Lilly/Boehringer	
Ingelheim)	
Semglee	(Mylan/Biocon)	
Rituximaba	 MabThera/Rituxan	
(Roche)	
Truxima/Blitzima/Ritemvia/Rituzena	
(Celltrion/Hospira)	
Teriparatided	 Forteo/Forsteo	(Eli	
Lilly)	
Movymia	(Stada	Arzneimittel)	
Terrosa	(Gedeon	Richter/Mochida	
Pharmaceutical)	
Trastuzumaba	 Herceptin	(Roche)	 Ontruzant	(Samsung	Bioepis/Merck)	
*Hyperlinks	are	to	entries	in	the	GaBi	(Generics	and	Biosimilars	Initiative)	website	(last	
accessed	15	June	2018)	
aMonoclonal	antibodies;	bGlycoproteins;	cFusion	protein;	dPolypeptide	hormones	
	
Table	2.	Current	percentage	uptakes	of	three	biosimilars	in	hospitals	
	
	
Drug	
Percentage	uptake	
Median	 Interquartile	range	
Etanercept	 76%	 60–90%	
Infliximab	 90%	 85–98%	
Rituximab	 60%	 42–76%	
	
	
	 	
  
Figure
in	Engl
	
Refere
            
1.	 Ala
rhe
of	a
74
2.	 Aro
3. Wa
Fin
832
4.	 Eur
htt
stin
5.	 Pal
Str
	1.	Number
ish	Clinical
nces	
                  
dul	MI,	Fit
umatology
	budget	im
11(17)309
nson	JK,	F
rd A. Copy
ancial Tim
42733f755
opean	Me
p://www.e
g/docume
mer	SC,	Sa
ippoli	GF.	T
s	of	items	
	Commissi
	
                  
zpatrick	RW
	and	gastr
pact	analy
78‐6.	doi:	1
erner	RE.	H
cat drugma
es April 17,
.html#axzz
dicines	Age
ma.europ
nt_listing_
glimbene	V
he	relativ
prescribed
oning	Grou
 
,	Chapma
oenterolog
sis.	Res	So
0.1016/j.s
ow	simila
kers team u
 2016. http
48FGMZe6
ncy,	Biosim
a.eu/ema/
000318.jsp
,	Mavridis
e	safety	an
	as	Abasag
p	as	at	Ap
	
	
n	SR.	The	
y	specialit
cial	Adm	P
apharm.20
r	are	biosi
p to help U
://www.ft.c
E. Last acc
ilar	medi
index.jsp?c
.	Last	acce
	D,	Salanti	
d	effective
lar	per	100
ril	2018	
effect	of	ne
ies	on	UK	h
harm	2018
18.05.009
milars?	BM
K make m
om/cms/s/0
essed 10 M
cines.	
url=pages
ssed	14	Ju
G,	Craig	JC,
ness	of	diff
0	items	of
w	biosimil
ealthcare	
.	pii:	S155
.	[Epub	ah
J	2016;	35
ore use of c
/398f5e6a-
ay 2016. 
/special_to
ne	2018.	
	Tonelli	M,
erent	epoe
	insulin	gla
ars	in	
budgets:	re
1‐
ead	of	prin
3:	i2721.	
heaper drug
0324-11e6-
pics/docu
	Wiebe	N,	
tin	drugs	f
5
rgine,	
sults	
t]	
s. 
99cb-
ment_li
or	
  6
                                                                                                                                                        
treating	anaemia	in	people	with	chronic	kidney	disease.	Cochrane	Database	Syst	
Rev	2014;	12:	CD010590.	
6.	 Combe	C,	Tredree	RL,	Schellekens	H.	Biosimilar	epoetins:	an	analysis	based	on	
recently	implemented	European	Medicines	Evaluation	Agency	guidelines	on	
comparability	of	biopharmaceutical	proteins.	Pharmacotherapy	2005;	25(7):	954‐
62.	
7.	 International	Conference	on	Harmonization.	ICH	Harmonised	Tripartite	Guideline.	
Comparability	of	biotechnological/biological	products	subject	to	changes	in	their	
manufacturing	process.	Q5E.	18	November	2004.	
https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality
/Q5E/Step4/Q5E_Guideline.pdf.	Last	accessed	14	June	2018.	
8.	 European	Medicines	Agency.	Committee	for	Medicinal	Products	for	Human	Use.	
CHMP/437/04	Rev	1.	Guideline	on	similar	biological	medicinal	products.	23	
October	2014.	
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/20
14/10/WC500176768.pdf.	Last	accessed	14	June	2018.	
9.	 US	Food	and	Drug	Administration.	Scientific	considerations	in	demonstrating	
biosimilarity	to	a	reference	product.	guidance	for	industry.	
http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation
/Guidances/UCM291128.pdf.	Last	accessed	14	June	2018.	
10.	 National	Institute	for	Health	and	Care	Excellence.	NICE’s	biosimilars	position	
statement.	August	2016.	https://www.nice.org.uk/Media/Default/About/what‐we‐
do/NICE‐guidance/NICE‐technology‐appraisals/Biosimilar‐medicines‐postition‐
statement‐aug‐16.pdf.	Last	accessed	14	June	2018.	
11.	 National	Institute	for	Health	and	Care	Excellence.	NICE	issues	draft	guidance	
recommending	drugs	for	rheumatoid	arthritis.	2	September	2015.	
https://www.nice.org.uk/news/press‐and‐media/nice‐issues‐draft‐guidance‐
recommending‐drugs‐for‐rheumatoid‐arthritis.	Last	accessed	14	June	2018.	
  7
                                                                                                                                                        
12.	 National	Institute	for	Health	and	Care	Excellence.	TNF‐alpha	inhibitors	for	
ankylosing	spondylitis	and	non‐radiographic	axial	spondyloarthritis.	1	February	
2016.	https://www.nice.org.uk/guidance/ta383.	Last	accessed	14	June	2018.	
13.	 National	Institute	for	Health	and	Care	Excellence.	Infliximab,	adalimumab	and	
golimumab	for	treating	moderately	to	severely	active	ulcerative	colitis	after	the	
failure	of	conventional	therapy.	25	February	2015.	
https://www.nice.org.uk/guidance/ta329.	Last	accessed	14	June	2018.	
14.	 European	Medicines	Agency.	Committee	for	Medicinal	Products	for	Human	Use.	
EMA/CHMP/589317/2013.	Assessment	report	Remsima.	
EMA/CHMP/589317/2013.	27	June	2013.	
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐
_Public_assessment_report/human/002576/WC500151486.pdf.	Last	accessed	14	
June	2018.	
15.	 World	Health	Organization.	WHO	to	begin	pilot	prequalification	of	biosimilars	for	
cancer	treatment.	2	June	2018.	http://www.who.int/news‐room/headlines/04‐05‐
2017‐who‐to‐begin‐pilot‐prequalification‐of‐biosimilars‐for‐cancer‐treatment.	Last	
accessed	14	June	2018.	
16.	 Høivik	ML,	Buer	LCT,	Cvancarova	M,	Warren	DJ,	Bolstad	N,	Moum	BA,	Medhus	AW.	
Switching	from	originator	to	biosimilar	infliximab—real	world	data	of	a	prospective	
18	months	follow‐up	of	a	single‐centre	IBD	population.	Scand	J	Gastroenterol	2018:	
1‐8.	doi:	10.1080/00365521.2018.1463391.	[Epub	ahead	of	print].	
17.	 Inotai	A,	Prins	CPJ,	Csanádi	M,	Vitezic	D,	Codreanu	C,	Kaló	Z.	Is	there	a	reason	for	
concern	or	is	it	just	hype?	‐	A	systematic	literature	review	of	the	clinical	
consequences	of	switching	from	originator	biologics	to	biosimilars.	Expert	Opin	Biol	
Ther	2017;	17(8):	915‐26.	
18.	 McKinnon	RA,	Cook	M,	Liauw	W,	Marabani	M,	Marschner	IC,	Packer	NH,	Prins	JB.	
Biosimilarity	and	interchangeability:	principles	and	evidence:	a	systematic	review.	
BioDrugs	2018;	32(1):	27‐52.	
  8
                                                                                                                                                        
19.	 Open	Prescribing.	https://openprescribing.net.	Last	accessed	16	June	2018.	
20.	 Medicines	Optimisation	Dashboard.		
https://apps.nhsbsa.nhs.uk/MOD/AtlasTrustsMedsOp/atlas.html.	Last	accessed	16	
June	2018.	
21.	 NHS	Indicative	prices.	British	National	Formulary.	https://bnf.nice.org.uk/.	Last	
accessed	21	June	2018.	
22.	 Rezk	MF,	Pieper	B.	To	See	or	NOsee:	the	debate	on	the	nocebo	effect	and	optimizing	
the	use	of	biosimilars.	Adv	Ther	2018	Jun	5.	doi:	10.1007/s12325‐018‐0719‐8.	
[Epub	ahead	of	print]	
